Relafen and Azotaemia - a phase IV clinical study of FDA data

Summary:

Azotaemia is reported as a side effect among people who take Relafen (nabumetone), especially for people who are female, 60+ old, also take Lasix, and have Breast cancer.

The phase IV clinical study analyzes which people have Azotaemia when taking Relafen. It is created by eHealthMe based on reports of 5,961 people who have side effects when taking Relafen from the FDA, and is updated regularly.

What is Relafen?

Relafen has active ingredients of nabumetone. It is often used in arthritis. eHealthMe is studying from 6,243 Relafen users. Check the latest studies of Relafen.

What is Azotaemia?

Azotaemia (excess of urea or other nitrogenous compounds in the blood) is found to be associated with 689 drugs and 704 conditions by eHealthMe. Check the latest studies of Azotaemia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

5,961 people reported to have side effects when taking Relafen.
Among them, 26 people (0.44%) have Azotaemia.

Among these 26 people:

What is the gender of people who have Azotaemia when taking Relafen? *

female: 92.31 %
male: 7.69 %

What is the age of people who have Azotaemia when taking Relafen? *

What are other drugs people take besides Relafen? *

What are other side effects people have besides Azotaemia? *

Stress And Anxiety: 22 people, 84.62%
Anaemia (lack of blood): 21 people, 80.77%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 21 people, 80.77%
Oedema Peripheral (superficial swelling): 21 people, 80.77%
Pneumonia: 20 people, 76.92%
Primary Sequestrum (piece of dead bone that has become separated during the process of necrosis from normal/sound bone): 20 people, 76.92%
Confusional State: 20 people, 76.92%
Cellulitis (infection under the skin): 20 people, 76.92%
Osteomyelitis (infection of bone): 20 people, 76.92%
Skin Ulcer: 20 people, 76.92%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 7 people, 26.92%
Breast Cancer: 7 people, 26.92%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 7.69%
Type 2 Diabetes: 1 person, 3.85%
Pulmonary Tuberculosis (lungs tuberculosis): 1 person, 3.85%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 3.85%
Histiocytosis Haematophagic: 1 person, 3.85%
High Blood Pressure: 1 person, 3.85%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 3.85%
Chest Pain: 1 person, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Relafen and have Azotaemia?

- Check whether Azotaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Relafen:

Relafen (6,243 reports)

Azotaemia treatments and more:

Azotaemia (5,179 reports)

Browse all side effects of Relafen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Azotaemia:

Azotaemia (689 drugs)

Browse all the conditions that are associated with Azotaemia:

Azotaemia (704 conditions)

Related publications that referenced our studies

Hung SC, Liao KF, Hung HC, Lin CL, Lai SW, Lin CH, "Nabumetone use and risk of acute pancreatitis in a case-control study", Pancreatology, 2016 Jun .
Hung SC, Liao KF, Hung HC, Lin CL, Lai SW, Lin CH, "Nabumetone use and risk of acute pancreatitis in a case-control study", Pancreatology, 2016 Jun .

How the study uses the data?

The study uses data from the FDA. It is based on nabumetone (the active ingredients of Relafen) and Relafen (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.